| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4dae7331034b6b26116b7c2f7acb115 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-828
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-825 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57469
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
1978-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1980-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_569a6fc93b852b6d7aeb39ba89e65650
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1df7d1d00b1fa0887cdf87dad4f0062 |
| publicationDate |
1980-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-1087979-A |
| titleOfInvention |
Tumor specific glycoproteins and method for detecting tumorigenic cancers |
| abstract |
ABSTRACT OF THE DISCLOSURE A new class of glycoproteins has been found to be produced by human cancer cells and is not produced by normal cells and said glycoprotein is present in the sera of cancer patients. This tumor specific glycoprotein can be characterized by its isoelectric point of from about 4.2 to 4.6 and by the perchloric acid soluble fraction thereof having a sialic acid content of above about 0.065 mg/ml of initial serum sample. The presence of a tumorigenic cancer in a patient can be determined by detecting the presence of the tumor specific glycoprotein in the blood sera of a patient. |
| priorityDate |
1977-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |